Sanofi blood disorder drug gets FDA nod

Feb. 8, 2019

The FDA has approved a new drug to treat a rare blood disorder. 

The medication, Cablivi, targets a condition called thrombotic thrombocytopenic purpura (aTTP).  The autoimmune disease can cause clots in small blood vessels, which can subsequently trigger fatal heart attacks and strokes. According to Sanofi, about 20 percent of patients die from aTTP within 30 days of being diagnosed. 

Sanofi says that Cablivi, which is designed to work in combination with standard-of-care treatments, is a first-of-its kind drug that can inhibit the formation of clots in patients with aTTP. 

The FDA said that Cablivi will have to come with a warning about the risk of severe bleeding.  

Read the full Reuters report.